UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 10K/A
AMENDMENT 1

|X| ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934

FOR THE FISCAL YEAR ENDED DECEMBER 31, 2002

|_| TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934

FOR THE TRANSITION PERIOD FROM TO

COMMISSION FILE NUMBER 0-49824

INAMCO INTERNATIONAL CORP.
(Exact name of registrant as specified in its charter)

DELAWARE 72-1359595
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)

801 MONTROSE AVE., SOUTH PLAINFIELD, NJ 07080
(Address of principal executive offices) (Zip Code)

(908) 754-4880 (Registrant's
telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days.

Yes |X| No |_|

Indicate by check mark if disclosure of delinquent filers pursuant to
Item 405 of Regulation S-K (Section 229.405 of this chapter) is not contained
herein, and will not be contained, to the best of the registrant's knowledge, in
the definitive proxy or information statements incorporated by reference in Part
III of this Form 10k or any amendment to this Form 10k |_|

The approximate aggregate market value of the voting and non-voting
common equity held by non-affiliates of the registrant was approximately
$276,000 as of July 30, 2003, based upon the closing price of the Common
Stock as reported on the Nasdaq Stock Market Pink Sheets on such date. For
purposes of this calculation, shares of Common Stock held by directors and
officers and stockholders whose ownership in the registrant is known by the
registrant to exceed five percent have been included. This number is provided
only for purposes of this report and does not represent an admission by either
the registrant or any such person as to the status of such person.

As of July 30, 2003 there were 27,600,000 shares of the registrant's
Common Stock outstanding.

INAMCO INTERNATIONAL CORP.

INDEX
NO. PAGE
- --- ----

Item 1. Business 3
Item 2. Properties 8
Item 3. Legal Proceedings 8
Item 4. Submissions of Matters to a Vote of Security Holders 8

Item 5. Market for the Registrant's Common Equity and Related Stockholder Matters 8
Item 6. Selected Financial Data 9
Item 7. Management's Discussion and Analysis of Financial Condition and Results of
Operations 9
Item 7A. Quantitative and Qualitative Disclosures about Market Risk 12
Item 8. Financial Statements and Supplementary Data 12
Item 9. Changes in and Disagreements with Accountants on Accounting and Financial
Disclosure 21
Item 10. Directors and Executive Officers of the Registrant 21
Item 11. Executive Compensation 22
Item 12. Security Ownership of Certain Beneficial Owners and Management 22
Item 13. Certain Relationships and Related Transactions 23

Item 14. Exhibits, Financial Statement Schedules and Reports on Form 8-K 23

INFORMATION RELATING TO FORWARD-LOOKING STATEMENTS

This annual report on Form 10K includes statements that could be
construed as "forward-looking" in nature. For such statements, we claim the
protection of the Private Securities Litigation Reform Act of 1995. Readers of
the Form 10 are cautioned, not to place undue reliance on these statements,
which speak only as of the date on which they are made. These statements involve
a number of risks and uncertainties, which include statements about the
Company's strategy and goals, and other statements that are not historical
facts. Some of the statements are preceded by the words "intends," "will,"
"plans," "expects," "anticipates," "estimates," "aims," and "believes" or
similar words. The Company undertakes no obligation to update publicly or revise
any of these statements. Actual events or results may differ materially from the
Company's expectations. Important factors that could cause actual results to
differ materially from those stated or implied by any statement include, but are
not limited to, the following: the ability to complete, if at all, within a
reasonable time period; future quarterly or annual financial results; the
timing, success and cost of research and development, and out-licensing
endeavors.

ITEM 1. BUSINESS.

GENERAL DEVELOPMENT OF BUSINESS.

Inamco International Corp. ("Inamco", the "Company", or "Registrant") was
incorporated in Delaware on January 17, 1993 originally as Omni Assets, Inc.
("Omni). Omni, at the time of its inception, was established to operate as a
financial consulting firm, whose clients were to be other companies in need of
assistance in raising capital, and/or required advice on mergers and
acquisitions, or the hiring of management. Since the Company's inception in
1993, it has never been an operating concern and/or generated any revenues.

The Company is a developmental stage corporation as defined in Financial
Accounting Standards Board Statement No.7, and is a non-operating public shell,
meaning it has not commenced full-scale operations and has insignificant assets
and liabilities. Since its inception, the Company has not had any revenues or
earnings, and the future success of the Company is dependent on creating a
viable business and/or finding a suitable merger candidate.

In September of 1999, negotiations between Mr. Varges George, the president
and sole shareholder of Inamco Services Corp., a management company that owns
and operates two separate and wholly owned subsidiary companies: Medicos
Laboratories, Inc. and Advanced Diagnostics, Inc. (descriptions of which are
located elsewhere in this Form-10), and the directors and majority shareholders
of Omni began. Initially, the reasons behind the acquisition of Omni, revolved
around the possible merger of Mr. George's pharmaceutical company, Medicos
Laboratories, Inc., and Omni (as further described in this Form 10 report). All
immediate collaborations between the parties focused upon an entity, to be owned
by Mr. George, successfully merging with Omni. There was also a mutual
understanding between the parties that Royal Capital Corp. ("Royal"), a
consulting company to be retained, would act as a consultant and familiarize
itself with the merger between the two companies.

On October 26, 1999, Inamco International Corp., a Delaware Corporation,
being incorporated on the 18th day of October, 1999, merged with Omni in a
transaction solely for stock. Pursuant to the merger agreement, 1000 shares of
Inamco were exchanged for 22,712,500 shares of Omni. Once the merger was
completed, Inamco terminated its corporate existence and, in February of 2000,
the name of Omni Assets, Inc., was changed to Inamco International Corp. At the
completion of the merger, the Company's common stock had a par value of $.00001,
giving the value of those shares, issued as part of the merger, a worth of $227.

In October of 1999, a formal agreement was entered into with Royal. This
agreement paid Royal for consultation services connected with the merger of the
two companies. In consideration for those services, Inamco agreed to pay
1,355,365 shares of its restricted common stock to Royal and/or it designees.

In January of 2000, preliminary steps were taken to measure the
feasibility of a merger and/or acquisition of Medicos Laboratories, Inc.
("Medicos") by Inamco. Medicos, at the time, was a company dedicated to the
research, development and formulating manufacture of quality generic
pharmaceuticals. Generic pharmaceuticals, as a whole, have the same chemical and
therapeutic properties as their brand-named counterparts. Although typically
less expensive, they are required to meet the same governmental standards as the
brand-named drug, and most must receive approval from the appropriate regulatory
authority prior to manufacture and sale. A manufacturer cannot produce or market
a generic pharmaceutical until all relevant patents (and any additional
government-mandated market exclusivity periods) covering the original brand-name
product have expired. It was later deemed that Medicos was too much in its
infancy stage to be a realistic merger candidate. Although it was researching
formulations on certain generic pharmaceuticals, it did not have all of its
laboratory equipment, proper FDA and Good Manufacturing Procedures
certification(s), and/or any revenue producing contractual agreements. It was
recommended that any arrangements to merge the two companies be halted, until
such time, if any, that Medicos could become an operating pharmaceutical
company. At this time it appears that a merger with Medicos is unlikely.

In February of 2000, the Company entered into a collaborative agreement
with Royal, so that Royal could provide certain services to Inamco on a
non-exclusive and best efforts basis. Royal contracted to familiarize itself
with the business operations, prospects and management of Inamco, and make
certain recommendations in order to enhance the marketing of any future
products. In consideration of the foregoing, Inamco immediately agreed to tender
a total of 1,000,000 shares of its common stock to Royal and/or its designees.

In March of 2000, Inamco began to compensate Royal, as per their
contractual obligations. In the month of March, Inamco issued a total of
1,170,000 restricted common shares to Royal and/or their assigns.

In May of 2000, Inamco continued their compensation to Royal with an
additional issuance of 1,000,000 shares of restricted common stock to Royal
and/or their assigns.

In November of 2000, Inamco finalized the compensation to Royal with a
final issuance of 185,365 shares of restricted common stock to Royal and/or
their assigns.

As of November 2000, the Company had paid out a total of 2,355,365
restricted common shares to Royal Capital, and/or their assigns, as per the
parties' agreements (a list of Royal's assigns is located elsewhere in this
Form-10). The Company claims no knowledge, as to why Royal decided to issue a
certain number of its restricted common shares to certain designees. Inamco
acted within the purview of its contractual obligations, and Royal was paid
within the three different time frames as stated above. At the time in which the
agreements were signed between the parties, the value for the services to be
rendered by Royal, to the Company, equaled approximately $750,000 dollars, and
Royal agreed to accept restricted shares of common stock rather than cash.

The Company then began to initiate certain internal business procedures by
retaining the services of a lawyer and the consulting services of an investment
banker. The Company agreed to issue 25,000 and 68,245 shares of restricted
common stock, respectably, to each. For legal services rendered, shares were
issued in May of 2000, and in November of 2000, shares were issued for
consultation services (descriptions of which can be found in other sections of
this Form-10).

Since the Company's inception, the ability to achieve and identify certain
goals or objectives has been dependent upon many factors, some of which are out
of the Company's control. The ability of the Company to merge with an operating
pharmaceutical company will depend upon many factors, including the
identification of a proper merger candidate, the size of any future
collaborations, the success rate of future marketing strategies, and general and
industry-specific economic conditions which may affect any and all future
business expenditures. As a consequence, the likelihood of the Company to
produce any revenues in the future is dependent solely on a merger and/or
acquisition, the success of which may never be achieved.

At present, the Company has never had any subsidiaries, and is currently
not the subject of, or engaged in, any bankruptcy, receivership or similar
proceedings. There has been no material reclassification, merger, consolidation,
or any acquisition or disposition of any material amount of assets to or from
the Company, and the Company has undergone no structural changes since the
merger of Inamco and Omni. The Company's common stock presently trades on the
over-the-counter pink sheets under the symbol IICO.PK and as of July 30, 2003,
the Company had 27,600,000 shares outstanding with a last trade bid price of
$0.01.

PLAN OF OPERATION.

FINANCIAL INFORMATION ABOUT SEGMENTS. The information required by this
section calls for a report on each segment, as defined by generally accepted
accounting principals, revenues from external customers, a measure of profit or
loss and total assets, as described by Regulation S-K (Subpart 229.101). The
Company must report this information for each of the last three fiscal years or
for as long as it has been in business, whichever period is shorter. The
information provided for in this section does conform with generally accepted
accounting principals and is included in, and can be crossed referenced to our
audited financial statements.

NARRATIVE DESCRIPTION OF BUSINESS. At present, the Company has yet to
commence any operations, and does not own any intellectual properties
whatsoever. All future business is hypothetical and predicated on the successful
merger with an established pharmaceutical manufacturer, which cannot be relied
upon and/or guaranteed.

If a successful merger is to be consummated with an existing pharmaceutical
manufacturer, the proper candidate will need to be an established pharmaceutical
company that presently manufactures and distributes certain generic
over-the-counter ("OTC") and prescription drugs. Current management of the
Company has determined, that any candidate to be acquired or merged with, may
need to have the ability to manufacture generic drugs whose equivalents are
Actifed(R), Allerest(R), Anacin(R), Co-Tylenol(R), Exlax(R), Sudafed(R), and/or
NightQuil(R). The candidate should also be in the position to produce other OTC
drugs and/or generic prescription medications.

If a merger and/or acquisition should be consummated, Inamco believes that it
may be in a position to sell its future products acquired in a the merger to
distributors (both domestic and international), hospitals, and large buying
groups. However, the Company is not currently in a position to sell its future
products to such groups. The Food and Drug Administration ("FDA") oversees the
manufacture of both brand-name and generic pharmaceuticals, and the production
of these drugs is usually subject to:

(1) An approved New Drug Application ("NDA") which allows the
medication to state both its safety and effectiveness;
(2) Marketed under an NDA for safety only;
(3) Marketed without an NDA; or
(4) Marketed pursuant to over-the-counter monograph regulations.

For generic pharmaceuticals being manufactured for both safety and
effectiveness, prior to marketing, these drugs must undergo and pass an
Abbreviated New Drug Application ("ANDA"). The Company realizes that in order to
get approval from the FDA via an ANDA, all drug product applications will need
to include: data relating to product formulation, raw material suppliers,
stability information, manufacturing techniques, packaging, labeling, and
quality control information. Those drugs subject to an ANDA under the Drug Price
Competition and Patent Term Restoration Act of 1984 (the "Waxman-Hatch Act")
must also contain bio-equivalency data. Generics can also be marketed by
adhering to FDA enforcement policies, or be subject to an over-the-counter drug
review monograph process. At present, Inamco has not prepared or submitted any
ANDA applications; it is contemplated however that certain applications may be
submitted based on certain drugs that Inamco may manufacture if a merger is
consummated.

If a successful merger and/or acquisition is consummated, the Company will
be immediately subject to the following FDA enforcement policies and
over-the-counter drug review monograph processes with respect to those certain
generic drugs wished to be manufactured and marketed:

o Comply with Standard Operating Procedures and Good Manufacturing
Practices which include:
o The development of a drug formulation that matches the Brand
product that is to be reproduced (i.e. assay, content uniformity,
dissolution profiles, and stability)
o The manufacture of a pilot batch that will equal 1/10 the size of
the actual production batch
o Test and validate both the manufacture process and the drug
potency of the pilot batch
o Generate stability data covering a 3 month time frame in which a
portion of the pilot batch will be subjected to a constant
temperature of 40 degrees centigrade and 75% relative humidity
o Generate stability data covering a long-term time frame (12
months) in which a portion of the pilot batch will be subjected
to a constant temperature of 25 degrees centigrade and a 60%
relative humidity
o Upon successful stability studies for the 3 month time frame, the
product is ready for mass production and marketing o The
manufacture of 3 production sized batches in which the
manufacture process as well as drug potency will be tested and
validated
o Prepare and submit final documentation to State Formulary
committees, to obtain an approval from each State so that the
product may be reimbursed through insurance companies and
Medicaid.

After a merger and/or acquisition is consummated, and if the candidate
company should not have any business relationships with manufacturers of raw
chemicals, or if any relationship is deemed "not being in the best interest" of
Inamco; the Company will then identify other sourcing chemical companies where
raw materials can be purchased in bulk for the manufacture of its generic
pharmaceuticals. All raw chemicals needed are readily available; however, it
will be the Company's intention to always be conscious of pricing, for certain
chemical companies will give discounts when buying in bulk and placing continual
orders. It will be Inamco's expectation to benefit from the fact that the
pharmaceutical industry is non-cyclical and the need for quality generic drugs
is always present. At present, Inamco has not identified any sourcing chemical
companies where raw materials could be purchased. If any company to be acquired
should not have a business relationship(s) with a sourcing chemical company,
Inamco will begin the identification process once a merger is consummated, a
course of action that should not take more than one month.

A proper merger candidate will also have its good manufacturing procedures
("GMP") certification issued by the FDA. This certification will allow Inamco to
produce certain generic pharmaceuticals to sell to future clientele. Coinciding
with expected revenues generated, Inamco will submit several different ANDA
applications to the FDA, so that it may manufacture certain prescription
medication and add considerable profit potential to its entire pharmaceutical
operation. At present, Inamco has no clientele or business operations and will
rely on a merger in order to generate future business, as well as a client list
of wholesalers and distributors.

It will be Inamco's future intention not to have a single customer or group
of customers comprising more than 20% of its revenue stream. The Company will
continue to add to its client base by tendering offers through certain buying
groups, municipalities, government agencies, hospital and retail distributors.
This will ensure enough of a customer base, so that the loss of any one client
will not significantly affect the Company's revenue stream.

Since the Company has yet to begin any operations, it has no backlogged
orders or government contracts subject to renegotiation or termination. At
present the Company has no competition as well. It is contemplated, however that
if a merger and acquisition is successful, the Company will have competition
with other manufacturers of generic pharmaceuticals. These competitors will
probably have substantially greater capital resources than Inamco, as well as
seasoned sales and marketing teams in place. It is the Company's belief that its
primary competition will come from other manufacturers of generic
pharmaceuticals, brand name pharmaceutical companies that also produce generic
drugs, the original manufacturer of the brand named drug in which the generic
is derived, and brand named pharmaceutical companies that can produce new drugs
for the same malady as the Company's proposed manufactured generic drug.

Inamco has not spent any monies on company-sponsored research and
development activities, and there are no plans to do so in the foreseeable
future. Once a merger and/or acquisition is consummated, the Company intends to
be in compliance with all federal, state and local provisions with respect to
the manufacture of generic pharmaceuticals. The FDA will oversee and enforce
compliance for good manufacturing practices, and it is the Company's additional
intention to locate a manufacturing facility located in a properly zoned
manufacturing area.

RISK FACTORS

RISKS INHERENT IN A DEVELOPMENT STAGE COMPANY. The Company was incorporated
in Delaware on January 17, 1983 originally as Omni Assets, Inc. On October 26,
1999, Inamco International Corp., a Delaware Corporation being incorporated on
the 18th day of October 1999, merged with Omni in a transaction solely for
stock. In February of 2000, the name of Omni was changed to Inamco International
Corp. Since the Company's inception, it has been engaged almost exclusively in
organizational activities and has just recently begun the search for a
pharmaceutical merger candidate, so that it may enter into the generic
pharmaceutical manufacturing arena. Accordingly, as a transitional development
stage company, the Company has had no operating history upon which an evaluation
of the Company's prospects can be determined. Consequently, the likelihood of
success of the Company must be considered in view of all of the risks, expenses
and delays inherent in the establishment of a new business, including, but not
being limited to, expenses and delays of an ongoing business that has commenced,
slower than anticipated manufacturing and marketing activities, the uncertainty
of market assimilation of the Company's product and other unforeseen factors.

RISKS RELATING TO A MERGER. It must noted that the Company has not
identified a suitable merger candidate to date, and no assurance can be made
that a candidate will ever be found. Accordingly, the likelihood that the
Company may merge with an ongoing pharmaceutical company must be considered in
view of all of the risks, expenses and delays inherent to a merger, including,
but not being limited to, expenses, agreements and delays of merging one
business with another, due diligence compilation, shareholder approval,
regulatory approval, legal and accounting reviews, and any other unforeseen
factors that are to effect the Company's ability to merge with a pharmaceutical
concern.

NO OPERATING HISTORY; LOSSES. The Company has had no business
operations and no prior operating history. The Company anticipates that it will
continue to incur losses and generate negative cash flow once a merger and
acquisition has been consummated. At this time, the Company has no revenues; and
there is no assurance that the Company will ever have revenues or be profitable
or achieve positive cash flow from operations. Since October of 1999, the
Company has incurred a total loss of $37,243 up and until March 31, 2003.

DEPENDENCE UPON KEY PERSONNEL. The success of the Company depends, in
part, upon the successful performance of its president and secretary, Mr. Varges
George. Mr. George at present is the sole executive and director of the Company.
He has complete and exclusive control as to all aspects of the Company's
direction and operation. The Company had entered into a one year comprehensive
employment contract with Mr. George dated October 27, 1999. The contract engaged
Mr. George to provide exclusive services to the Company for a total of one year,
and then to render his services from time to time, as per the discretion of the
Company's director (Mr. George being that director). Although Mr. George owns
another company, as described in other sections of this Form 10, he has never
broken the exclusivity clause between the time frames of October 27, 1999 and
October 26, 2000, for the reason that he remained within the confines of his
employment agreement, while qualifying and quantifying possible business
acquisition and/or merger. Mr. George's compensation was a one-time payment of
one million shares of Inamco International, Corp. common stock (a copy of the
Agreement is attached hereto). If a merger and/or acquisition is consummated,
the Company intends to elect a board of directors, who will employ additional
qualified executives, employees and consultants having significant experience in
delivering the business expertise needed. In the interim, if Mr. George should
fail to perform any of the duties undertaken by him, for any reason whatsoever,
the ability of the Company to find a merger candidate, so that manufacturing,
marketing and distribution of generic pharmaceutical may begin, could be
adversely affected. The Company may seek in the future to secure and maintain
key man insurance on Mr. George; there is no assurance, however, that such
insurance will in fact be obtained. Moreover, the Company believes there are
available qualified managerial and other personnel in sufficient numbers to
properly staff the facilities and offices of the Company, but there can be no
assurance that the Company will be able to attract sufficient qualified
personnel.

REGULATION. The Company, as well as all participants in the generic over
the counter pharmaceutical industry, must comply with the rules and regulations
of the Food and Drug Administration. ("FDA"). The manufacture of generic drugs
is governed by FDA regulations and protocols. Such regulations and protocols are
subject to change. Therefore, the Company's approach to certification, if a
merger should occur, may require modifications to adjust for future regulatory
change. Furthermore, the Company's future activities (although less intense than
more established pharmaceutical manufacturers who are principally engaged in the
manufacture of controlled drug products) are subject to extensive regulation not
only by the FDA, but comparable state regulatory and foreign health authorities.

COMPETITION. If a merger should occur between the Company and a
pharmaceutical concern, it is the Company's belief that there are manufacturing
entities that currently offer products and services similar to those to be
proposed by the Company. These entities may have greater financial and personnel
resources than the Company. Manufacture and use of generic over the counter
("OTC") drugs throughout the United States is on the increase. The generic OTC
manufacturing industry, in general, is dominated by a small number of companies,
which are well known to the public.

THERE IS A POTENTIAL CONFLICT OF INTEREST OF THE COMPANY'S PRESIDENT IF
THE COMPANY ACQUIRES AN INDEPENDENT PHARMACEUTICAL COMPANY OR BEGINS
NEGOTIATIONS WITH MEDICOS LABORATORIES, INC. Mr. Varges George is currently the
president; and sole shareholder of Inamco Services Corp. which is totally
independent from, and should not be confused with Inamco International Corp.
This management company owns and operates two separate wholly owned subsidiary
companies, one of which is a generic pharmaceutical manufacturer, Medicos
Laboratories, Inc. ("Medicos"). Medicosoperates primarily as a laboratory
engaged in the development and manufacture of non-prescription and prescription
generic drugs. Among the products being produced are: clinical chemical
reagents, tablets, chewable tablets, capsules, liquids and powders. It should be
noted that if Inamco International Corp. should acquire and/or merge with
another pharmaceutical company other than Medicos Laboratories Inc., there would
be a conflict of interest resulting form Mr. George's 100% ownership in Medicos
and his majority ownership in Inamco International Corp. The control of both of
these competing companies would present a conflict of interest for Mr. George.
If this should occur, it will be the legal responsibility of Mr. George to
properly relinquish one of his executive roles, as well as any equity ownership,
within one of the competing companies.

POTENTIAL CONFLICT OF INTEREST REGARDING THE TIME SPENT BETWEEN COMPANIES.
As described elsewhere in this Form 10, the Company's president, Mr. Varges
George is currently the sole shareholder of Medicos Laboratories, Inc., a
company that manufactures generic pharmaceuticals; Mr. George was also party to
an exclusive employment contract between he and Inamco from October, 1999 to
October, 2000. Any potential conflicts of interest regarding Mr. George's time
spent, with respect to both companies, is resolved by the fact that Mr. George
has never been an officer or employee of Medicos and does not see to the
day-to-day operation of that company.

INAMCO'S COMMITMENT TO ISSUE AND REGISTER FOR RESALE A LARGE NUMBER
OF SHARES PURSUANT TOCONTRACTUAL OBLIGATIONS. In October of 1999, a formal
agreement was entered into
with Royal Capital, a consultation firm. This agreement paid Royal for
consultation services connected with certain merger activities had between Omni
and Inamco (as described elsewhere in this Form 10). In consideration for those
services, Inamco agreed to pay a total of 2,355,365 shares of restricted common
stock to Royal and/or its designees. As of June 2, 2003, Inamco had 27,600,000
shares issued and outstanding, inclusive of those restricted shares forwarded to
Royal and/or their designees. Therefore, should Royal and/or their designees
sell all or a large number of their common shares, once all restrictions are
lifted, it could reduce the per-share value of Inamco's common shares currently
traded on the NASDAQ pink sheets and currently held by existing investors.

EFFECTS ON THE FLUCTUATION OF COSTS AND AVAILABILITY OF RAW MATERIALS. If a
merger is to occur, the Company intends to purchase premium grade raw materials
for use in its generic drug manufacturing enterprise. Such unprocessed natural
products will be obtained from third party sources and manufacturing
sub-contractors. The price and availability of these raw materials are subject
to numerous factors not within the Company's control including: weather
conditions, policies of foreign countries and/or trade restrictions as well as
the status of the worldwide demand for generic drug ingredients. In the event
the Company cannot timely acquire its raw materials from third party entities,
the Company's ability to ship its products and service to its targeted markets
on a timely basis, if at all, would be negatively affected.

RELIANCE ON OUTSIDE SUPPLIERS. After a merger, the Company intends to
purchase its raw materials and supplies from independent sources. It will remain
dependent upon such outside sources for all of its unprocessed natural products.
There can be no assurance that these sources will be able to provide adequately
for the future needs to the Company. In the event that any of the Company's
future suppliers should suffer quality control problems, lack of raw materials
or financial difficulties, the Company would be required to find alternative
sources for its product lines. The Company believes that the likelihood that it
could identify a broad base of alternative sources is high based on the large
number of easily accessible and affordable producers of compounds for generic
drugs in the manufacturing marketplace. The time lost in seeking and acquiring
additional and newer sources, however could adversely affect the Company's
future revenues and profitability.

PRODUCT LIABILITY. The testing, marketing and sale of generic
pharmaceuticals entail an inherent risk of allegations of product liability, and
there can be no assurance that product liability claims will not be asserted
against the Company. Inamco may incur product liability due to product failure
or improper use of products by the user. The Company intends to obtain product
liability insurance that should be adequate for future operations. There can be
no assurance, however, that the amount of insurance, once obtained, will be
sufficient to fully insure against claims that may be made against the Company.
At present, the Company has not prepared or submitted any applications to the
Food and Drug Administration with respect to testing, marketing, or the sale of
generic pharmaceuticals; it is contemplated however that certain applications
may be submitted based on certain drugs that the Company may manufacture once a
merger is consummated. Once applications are submitted, the Company cannot state
when approvals will be had, if ever.

THE GENERIC DRUG ENFORCEMENT ACT OF 1992. Which was amended to the FDC
Act, gives the FDA six ways to penalize any entity that engages in wrongdoing
with respect to the development and/or manufacture of a generic drug, or the
purposefully faulty submission of an ANDA, which include, but are not limited
to:

1) Permanently or temporarily prohibit alleged wrongdoers from
submitting or assisting in the submission of an ANDA;
2) Temporarily deny approval of, or suspend applications to market
particular generic drugs;
3) Suspend the distribution of all drugs approved or developed
pursuant to an invalid ANDA;
4) Withdraw approval of an ANDA;
5) Seek civil penalties; and/or
6) Significantly delay the approval of any pending ANDA from the
same party.

At present, the Company has never been the subject of any enforcement action by
the FDA (and/or otherwise), and it is the intention of the Company to acquire a
pharmaceutical entity that itself has had no previous problems with the FDA.
There can be no assurances, however, that restrictions and/or fines will not be
imposed on Inamco in the future.

ITEM 2. PROPERTIES.

At present, the Company does not own any property, or is a part of any
long-term lease agreements.

ITEM 3. LEGAL PROCEEDINGS.

None.

ITEM 4. SUBMISSIONS OF MATTERS TO A VOTE OF SECURITY HOLDERS.

No matters were submitted to a vote of security holders during the
fourth quarter of the fiscal year covered by this report.

ITEM 5. MARKET FOR THE REGISTRANT'S COMMON EQUITY AND RELATED STOCKHOLDER
MATTERS.

Our common stock has traded on the Nasdaq Pink Sheets under the symbol
"IICO.PK" The following table sets forth, for the period indicated, the high and
low bid quotations for the common stock as reported by the Nasdaq Pink Sheets.

HIGH LOW
-------- --------
Year ended December 31, 2001
Third Quarter (from July 28, 2000) $ .08 $ .05
Fourth Quarter $ .05 $ .05

HIGH LOW
-------- --------
Year ended December 31, 2002
First Quarter $ .05 $ .01
Second Quarter $ .01 $ .01
Third Quarter $ .01 $ .01
Fourth Quarter $ .01 $ .01

On July 30, 2003, the last reported sale price on the Nasdaq pink
Sheets for our common stock was $0.01 per share.

As of July 30, 2003 there were approximately 50 stockholders of
record of the Company's common stock.

DIVIDENDS

We have never declared or paid any cash dividends on our capital stock
and do not anticipate paying any cash dividends in the foreseeable future.

USE OF PROCEEDS FROM THE SALE OF REGISTERED SECURITIES

The Company has not recorded and/or sold any registered securities for
the year ending December 31, 2002.

ITEM 6. SELECTED FINANCIAL DATA.

Reference is made to Selected Financial Data in "Item 8. Financial
Statements and Supplementary Data" included elsewhere in this Annual Report
Form 10k.

ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS.

You should read the following discussion and analysis in conjunction
with the Company's "Financial Statements and Supplementary Data" included
elsewhere in this Form 10k.

At present, the Company has yet to commence any operations, and does not
own any intellectual properties whatsoever. The Company is in the development
stage as defined in Financial Accounting Standards Board Statement No.7, and is
a non-operating public shell, meaning it has not commenced full-scale operations
and has insignificant assets and liabilities. Since its inception, the Company
has not had any revenues or earnings, and all future business is hypothetical
and predicated on the successful merger with an established pharmaceutical
manufacturer.

CRITICAL ACCOUNTING POLICIES AND MANAGEMENT ESTIMATES

It cannot be assured that the Company will have any accounting policies
and/or management estimates, based off of actual business operations, in the
foreseeable future. The initiation of these practices will only begin once a
successful merger with an established pharmaceutical manufacturer has been had.
However, the Securities and Exchange Commission defines critical accounting
policies as those that are, in management's view, most important to the
portrayal of the company's financial condition and results of operations and
most demanding of their judgment. Our discussion and analysis of our financial
condition and results of operations are based upon our consolidated financial
statements, which have been prepared in accordance with accounting principles
generally accepted in the US. The preparation of these financial statements
requires us to make estimates and judgments that affect the reported amounts of
assets, liabilities, revenues and expenses. We base our estimates upon
historical experience and on various other assumptions that are believed to be
reasonable under the circumstances, the results of which form the basis for
making judgments about the carrying values of assets and liabilities that are
not readily apparent from other sources. Actual results may differ from these
estimates under different assumptions or conditions. If the Company should merge
with an existing pharmaceutical company, our accounting policies will include:

Revenue Recognition. Our revenue recognition policies will be in
accordance with the Securities and Exchange Commission Staff Accounting Bulletin
(SAB) 101, Revenue Recognition in Financial Statements. SAB 101 provides
guidance related to revenue recognition based on the interpretations and
practices developed by the Securities and Exchange Commission. Some of our
future pharmaceutical manufacturing agreements may contain multiple elements,
including "downstream milestones" and royalty obligations.

If revenues are to occur from "milestones", cash flow is recognized when
earned, as evidenced by written acknowledgment from our collaborator, provided
that (i) the milestone event is substantive and its achievability was not
reasonably assured at the inception of the agreement, and (ii) our performance
obligations after the milestone achievement will continue to be funded by our
collaborator at a comparable level to, or before the milestone achievement. If
both of these criteria are not met, the milestone payment can be recognized over
the remaining minimum period of our performance obligations under the agreement.
If upfront fees are to be negotiated in any future contracts, they can be
recognized over a period of time relative to the services to be provided.

Goodwill and Intangibles. Purchase accounting requires accounting
estimates and judgments to allocate the purchase price of any future acquisition
to the fair market value of the assets and liabilities purchased. Any future
acquired technology can be amortized over its useful life. The estimated useful
life can be determined based on an analysis, as of any acquisition date, of
conditions in, and the economic outlook for, the pharmaceutical industries and
the patent life of that specific technology. As with any intangible asset, we
will evaluate the value of the technology and, if necessary, we will have a
future write-down of the carrying value of the technology. If it should be
determined that any technology has become impaired, that may accelerate the
amortization of any technology if it should be deemed that its life has been
shortened.

Income Taxes. At present, the Company has yet to commence any
operations, and does not own any intellectual properties whatsoever. Since its
inception, the Company has not had any revenues or earnings however, it is
contemplated that once business operations begin, we could record a valuation
allowance, in order to reduce our deferred tax assets. More consideration on
future taxable income and feasible tax planning strategies in assessing the need
for a valuation allowance will be had once a successful merger is completed.

The above is not intended to be a comprehensive list of all or any of
our present or future accounting policies. In many cases, the accounting
treatment of a particular transaction is specifically dictated by generally
accepted accounting principles, with no need for management's judgment in their
application. There are also areas in which management's judgment in selecting
any available alternative would not produce a materially different result. See
our audited consolidated financial statements and notes thereto in this Report
on Form 10k which contain accounting policies and other disclosures required by
generally accepted accounting principles.

YEAR ENDED DECEMBER 31, 2002 COMPARED TO THE YEAR ENDED DECEMBER 31, 2001

Revenues. We recorded no revenues for this time frame, and you should
read the following in conjunction with the Company's "Financial Statements and
Supplementary Data" included elsewhere in this Form 10k.

Research and Development Expenses. There has been no Research and
development expenses, and the following should be read with the Company's
"Financial Statements and Supplementary Data" included elsewhere in this Form
10k.

General and Administrative Expenses. General and administrative expenses
increased $8,701 to $9,226 for the year ended December 31, 2002 from $525 for
the year ended December 31, 2001. The increase was a result of general and
administrative expenses for Inamco, which consisted primarily of professional
fees and other general corporate expenses. We expect that our general and
administrative expenses will increase to support our growth and requirements as
a public company.

Amortization of Deferred Compensation. There has been no Amortization of
Deferred Compensation for the Company, and the following should be read with the
"Financial Statements and Supplementary Data" included elsewhere in this Form
10k.

Interest Income. Interest income was nominal for the year ended December
31, 2002 and the year ended December 31, 2001. This was due to a nominal cash
balance that did not exceed $950, at any given time, within the Company's
primary corporate account.

Interest Expense. Interest expense was nominal for the year ended
December 31, 2002 and the year ended December 31, 2001. This was due to a
nominal cash balance that did not exceed $950, at any given time, within the
Company's primary corporate account.

Gain on Investment. We recorded no Gains on Investment for this time
frame, for the Company does not own any long-term or short-term liquid financial
instruments, and you should read the following in conjunction with the Company's
"Financial Statements and Supplementary Data" included elsewhere in this Form
10k.

Other Income. We reported no Other Income for this time frame, and you
should read the following in conjunction with the Company's "Financial
Statements and Supplementary Data" included elsewhere in this Form 10k.

Non-Cash Preferred Stock Charge. We recorded no non-cash preferred stock
charge for this time frame, and you should read the following in conjunction
with the Company's "Financial Statements and Supplementary Data" included
elsewhere in this Form 10k.

YEAR ENDED DECEMBER 31, 2001 COMPARED TO THE YEAR ENDED DECEMBER 31, 2000

General and Administrative Expenses. General and administrative expenses
decreased $11,847 to $525 for the year ended December 31, 2001 from $12,372 for
the year ended December 31, 2000. The decrease was a result of the completion of
the merger as explained in other sections of this Form 10k. General and
administrative expenses for Inamco consist primarily of professional fees and
other general corporate expenses. We expect that our general and administrative
expenses will increase to support our growth and requirements as a public
company.

Interest Income. Interest income was nominal for the year ended December
31, 2001 and the year ended December 31, 2000. This was due to a nominal cash
balance that did not exceed $350, at any given time, within the Company's
primary corporate account.

Interest Expense. Interest expense was nominal for the year ended
December 31, 2001 and the year ended December 31, 2000. This was due to a
nominal cash balance that did not exceed $350, at any given time, within the
Company's primary corporate account.

LIQUIDITY AND CAPITAL RESOURCES

Liquidity refers to our ability to generate adequate amounts of cash to
meet our needs. We have been generating the cash necessary to fund our
operations from continual loans from the president and chief operating officer
of the Company, Mr. Varges George. We have incurred a loss in each year since
inception, and we expect to incur substantial losses for at least the next
several years. We expect that losses may fluctuate, and that such fluctuations
may be substantial. As of December 31, 2002, we had an accumulated deficit of
$35,624. Our accumulated deficit is the result of expenses incurred in
connection with our general and administrative costs, as well as the cost to
support the growth and requirements as a public company.

Potential immediate sources of liquidity are the continual loans from
Mr. George. Another potential source of liquidity is the sale of restricted
shares of our common stock.

As of December 31, 2002, we had $927 in cash compared to $38 in cash as
of December 31, 2001. The increase of $889 is primarily attributable to loans
provided for by the Company's president.

Net cash used in operating activities was approximately $9,226 during
the year ended December 31, 2002. The primary use of cash for the year ended
December 31, 2002 was to fund general and administrative costs, as well as the
cost to support the growth and requirements as a public company. Our net loss in
the period, adjusted for non-cash expenses, amortization, and changes in
operating assets and liabilities. Net cash used in operating activities was
approximately $525 during the year ended December 31, 2001.

Net cash provided by loans from Mr. George was approximately $9,226
during the year ended December 31, 2002. Net cash proceeds from loans by Mr.
George were $525 during the year ended December 31, 2001.

Since the Company is in the development stage as defined in Financial
Accounting Standards Board Statement No.7, and is a non-operating public shell,
meaning it has not commenced full-scale operations and has insignificant assets
and liabilities, we presently share an address with Inamco Services, Corp. At
present, the Company has no lease and pays no rent; our address is 801 Montrose
Avenue, South Plainfield, New Jersey, 07080.

Based on the possibility of a merger between Inamco and a pharmaceutical
company, we would expect to hire between 35 to 50 employees, primarily research
scientists and development staff. This is based off of the average industry
standard for a generic pharmaceutical company and the amount of employees that
they employ. While we believe that our current capital resources and anticipated
cash flows from a merger will not be sufficient to meet any future capital
requirements, we understand that additional financing will be needed. The
estimated length of time current cash and available borrowings will sustain our
operations is based on estimates and assumptions we have made. These estimates
and assumptions are subject to change at any time. We cannot assure you that
adequate funding will be available to us or, if available, that such funding
will be available on acceptable terms. Any shortfall in funding could result in
the curtailment of any merger activities.

INCOME TAXES

As of December 31, 2002, we had approximately $9,226 of net operating
losses for federal income tax purposes. These amounts reflect different
treatment of expenses for tax reporting than is used for financial reporting.
United States tax law contains provisions that may limit our ability to use net
operating losses in any year, or if there has been a significant ownership
change. Any future significant ownership change may limit the use of our net
operating losses.

ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

The Company is not exposed to any market risk due to the fact that it
does not own any risk sensitive instruments; all cash is used solely for the
purpose of maintaining a minimum balance within a corporate bank account and the
fluctuations that interest rates play on that cash is immaterial.

ITEM 8. FINANCIAL STATEMENTS.

INAMCO INTERNATIONAL CORP.
INDEX TO FINANCIAL STATEMENTS
PAGE
----

Report of Kahn Boyd Levychin & Company, Independent Auditors
Consolidated Balance Sheets
Consolidated Statements of Operations
Consolidated Statements of Stockholders' Equity (Deficit)
Consolidated Statements of Cash Flows
Notes to Consolidated Financial Statements

INAMCO INTERNATIONAL CORP.
(A DEVELOPMENT STAGE COMPANY)

YEARS ENDED DECEMBER 31, 2002, 2001 AND 2000

Report of Independent Certified Public Accountants F1

Financial Statements:

Balance Sheets F2

Statements of Operations F3

Statements of Cash Flows F4

Statements of Stockholders' Deficiency F5

Notes to Financial Statements F6-F7

-F-

REPORT OF INDEPENDENT CERTIFIED PUBLIC ACCOUNTANTS
--------------------------------------------------

BOARD OF DIRECTORS AND STOCKHOLDERS
INAMCO INTERNATIONAL CORP.

We have audited the accompanying balance sheet of INAMCO INTERNATIONAL CORP. (A
Development Stage Company) as of December 31, 2002, 2001 and 2000, and the
related statements of operations, stockholders' equity, and cash flows for the
years then ended. These financial statements are the responsibility of the
Company's management. Our responsibility is to express an opinion on these
financial statements based on our audit.

We conducted our audit in accordance with auditing standards generally accepted
in the United States of America. Those standards require that we plan and
perform the audit to obtain reasonable assurance about whether the financial
statements are free of material misstatement. An audit includes examining, on a
test basis, evidence supporting the amounts and disclosures in the financial
statements. An audit also includes assessing the accounting principles used and
significant estimates made by management, as well as evaluating the overall
financial statement presentation. We believe that our audit provides a
reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in
all material respects, the financial position of INAMCO INTERNATIONAL CORP., as
of December 31, 2002, 2001 and 2000, and the results of its operations and its
cash flows for the years then ended in conformity with accounting principles
generally accepted in the United States of America.

The accompanying financial statements have been prepared assuming that the
Company will continue as a going concern. As discussed in Note A to the
financial statements, the Company had a loss from operations and has a working
capital deficiency, raising substantial doubt about its ability to continue as a
going concern. Management's plans in regard to these matters are also described
in Note A. The financial statements do not include any adjustments relating to
the recoverability and classification of asset carrying amounts or the amounts
and classifications of liabilities that might result should the Company be
unable to continue as a going concern.

KAHN BOYD LEVYCHIN, LLP

New York, New York
March 31, 2003

-F1-

INAMCO INTERNATIONAL CORP.
(A DEVELOPMENT STAGE COMPANY)
BALANCE SHEETS
December 31, 2001, 2002 and 2000

December 31,
------------
2002 2001 2000
----- ----- ----

ASSETS
Current Assets
Cash $ 927 $ 38 $ 343
-------- -------- --------
Total Current Assets 927 38 343
Other Assets 213 213 213
-------- -------- --------
Total Assets $ 1,140 $ 251 $ 556
======== ======== ========

LIABILITIES AND STOCKHOLDERS' DEFICIENCY

LIABILITIES
Current Liabilities
Accounts payable and accrued expenses $ 5,615 $ 1,668 $ 1,148
-------- -------- --------
Total Current Liabilities 5,615 1,668 1,148
Due to Officer/Shareholder 8,069 1,900 2,200
-------- -------- --------
Total Liabilities 13,684 3,568 3,348

STOCKHOLDERS' DEFICIENCY
Common Stock, $.00001 par value
Authorized: 50,000,000 shares
Issued and Outstanding: 27,600,000 276 276 276
Additional paid-in capital 22,804 22,804 22,804
Deficit Accumulated in the Development Stage (35,624) (26,397) (25,872)
-------- -------- --------
Total Shareholders' Deficiency (12,544) (3,317) (2,792)
-------- -------- --------
$ 1,140 $ 251 $ 556
======== ======== ========

THE ACCOMPANYING NOTES ARE AN INTEGRAL PART OF THIS STATEMENT
-F2-

INAMCO INTERNATIONAL CORP.
(A DEVELOPMENT STAGE COMPANY)
STATEMENTS OF OPERATIONS
Years Ended December 31, 2002, 2001 and 2000

Inception
January 17, 1993 to Year Ended December 31,
-----------------------
December 31,2002 2002 2001 2000
---------------- ---- ---- ----

Net Sales $ - $ - $ - $ -
Cost of Goods Sold - - - -
---------------- ------------ ------------ ------------
Gross Profit - - - -

Costs and Expenses
Bank Charges and Miscellaneous 2,967 1,226 525 1,215
Professional and Consulting Fees 32,657 8,000 - 11,157
---------------- ------------ ------------ ------------
35,624 9,226 525 12,372
---------------- ------------ ------------ ------------

Net Loss $ (35,624) $ (9,226) $ (525) $ (12,372)
================ ============ ============ ============

Weighted Avereage Number of Shares Outstanding 9,323,472 27,600,000 27,600,000 25,871,020
---------------- ------------ ------------ ------------

Loss Per Share (A) $ (0.00) $ (0.00) $ (0.00) $ (0.00)
================ ============ ============ ============

(A) Loss per share less that $.01

THE ACCOMPANYING NOTES ARE AN INTEGRAL PART OF THIS STATEMENT
-F3-

INAMCO INTERNATIONAL CORP.
(A DEVELOPMENT STAGE COMPANY)
STATEMENTS OF CASH FLOWS
December 31, 2001 and 2000

Inception
January 17, 1993 to Year Ended December 31,
-----------------------
December 31,2002 2002 2001 2000
------------------ ---- ---- ----

Cash flows from operating activities:
Net loss $ (35,624) $ (9,226) $ (525) $(12,372)
Adjustments to reconcile net loss to net cash used in
operating activities
Change in accrued expenses 5,615 3,947 520 1,148
------------------ -------- -------- --------
Net cash used for operating activities (30,009) (5,279) (5) (11,224)
------------------ -------- -------- --------
Cash flows from investing activities:
Change in other assets (213) - - (213)
------------------ -------- -------- --------
Net cash used for investing activities (213) - - (213)
------------------ -------- -------- --------
Cash flows from financing activities:
Loans from officer/shareholder, net of repayments 8,068 6,168 (300) 2,200
Restricted common stock issued in payment of expenses 22,868 - - 9,367
Issuance of restricted common stock in connection
with merger agreement 213 - - 213
------------------ -------- -------- --------
Net cash provided by financing activities 31,149 6,168 (300) 11,780
------------------ -------- -------- --------
NET INCREASE (DECREASE) IN CASH 927 889 (305) 343
Cash at beginning of period - 38 343 -
------------------ -------- -------- --------

Cash at end of period $ 927 $ 927 $ 38 $ 343
================== ======== ======== ========

THE ACCOMPANYING NOTES ARE AN INTEGRAL PART OF THIS STATEMENT
-F4-

INAMCO INTERNATIONAL CORP.
(A DEVELOPMENT STAGE COMPANY)
STATEMENTS OF STOCKHOLDERS' EQUITY
Inception January 17, 1993 to December 31, 2002

Deficit
Accumulated
Additional in the
Common Stock $.00001 Par Value Paid-In Development
Shares Amount Capital Stage Total
---------- ---------- --------- ---------- ----------

Issuance of restricted common stock for services 437,500 $ 4 $ 1,996 $ - $ 2,000
Net Loss for the year ended December 31, 1983 - - - (2,000) (2,000)
---------- ---------- --------- ---------- ----------

Balance at December 31, 1983 437,500 4 1,996 (2,000) -
Issuance of restricted common stock for services 1,850,000 19 11,481 11,500
Net Loss for the year ended December 31, 1997 - - - (11,500 (11,500)
---------- ---------- --------- ---------- ----------

Balance at December 31, 1997 2,287,500 23 13,477 (13,500) -
Net Loss for the year ended December 31, 1998 - - - - -
---------- ---------- --------- ---------- ----------

Balance at December 31, 1998 2,287,500 23 13,477 (13,500) -
Net Loss for the year ended December 31, 1999 - - - - -
---------- ---------- --------- ---------- ----------

Balance at December 31, 1999 2,287,500 23 13,477 (13,500) -

Net Loss for the year ended December 31, 2000 - - - (12,372) (12,372)
Issuance of restricted common stock for services 2,600,000 26 9,327 - 9,353
Issuance of restricted common stock in
connection with agreement 22,712,500 227 - - 227
---------- ---------- --------- ---------- ----------

Balance at December 31, 2000 27,600,000 276 22,804 (25,872) (2,792)
Net Loss for the year ended December 31, 2001 - - - (525) (525)
---------- ---------- --------- ---------- ----------

Balance at December 31, 2001 27,600,000 276 22,804 (26,397) (3,317)
Net Loss for the year ended December 31, 2002 - - - (9,227) (9,227)
---------- ---------- --------- ---------- ----------

Balance at December 31, 2002 27,600,000 $ 276 $ 22,804 $ (35,624) $ (12,544)
========== ========== ========= ========== ==========

THE ACCOMPANYING NOTES ARE AN INTEGRAL PART OF THIS STATEMENT
-F5-

INAMCO INTERNATIONAL CORP.
(A Development Stage Company)
NOTES TO FINANCIAL STATEMENTS
Years Ended December 31, 2002, 2001 and 2000

NOTE A - ORGANIZATION AND BASIS OF PREPARATION

Inamco International Corp. ("the Company") was incorporated in Delaware on
January 17, 1983 originally as Omni Assets, Inc. ("Omni"). On October 26, 1999,
Inamco International Corp. ("Inamco"), a Delaware corporation, merged with Omni
in a transaction solely for stock. Pursuant to the merger agreement, 1,000
shares of the original Inamco were exchanged for 22,712,500 shares of Omni,
Inamco terminated its corporate existence and, in February 2000, the name of
Omni was changed to Inamco International Corp.

The Company's financial statements have been presented on a going concern basis,
which contemplates the realization of assets and the satisfaction of liabilities
in the normal course of business. The Company has no significant assets, no
revenues and has had losses since inception. The Company can only become a
viable going concern if it obtains additional capital and acquires a viable
operating company.

NOTE B - SUMMARY OF ACCOUNTING POLICIES

A summary of the significant accounting policies consistently applied in the
preparation of the accompanying financial statements follows.

1. BASIS OF ACCOUNTING

Financial statements are prepared on the accrual basis of accounting.

2. USE OF ESTIMATES

In preparing financial statements in conformity with accounting principles
generally accepted in the United States of America, management is required to
make estimates and assumptions that affect the reported amounts of assets and
liabilities and the disclosure of contingent assets and liabilities at the date
of the financial statements and revenues and expenses during the reporting
period. Actual results could differ from those estimates.

3. CASH AND CASH EQUIVALENTS

The Company considers all highly liquid investments purchased with original
maturities of three months or less to be cash equivalents.

4. INCOME TAXES

The Company accounts for income taxes under the provisions of Statement of
Financial Accounting Standards No. 109, Accounting for Income Taxes. This
statement requires, among other things, an asset and liability approach for
financial accounting and reporting of deferred income taxes. In addition, the
deferred tax liabilities and assets are required to be adjusted for the effect
of any future changes in the tax law or rates. Deferred income taxes arise from
temporary differences resulting in the basis of assets and liabilities for
financial reporting and income tax purposes. A valuation allowance is provided
if the Company is uncertain as to the realization of deferred tax assets.

F-6

INAMCO INTERNATIONAL CORP.
(A Development Stage Company)
NOTES TO FINANCIAL STATEMENTS
Years Ended December 31, 2002, 2001 and 2000

5. LOSS PER SHARE

Statement of Financial Accounting Standards No. 128 (SFAS No. 128), Earnings per
Share, specifies the computation, presentation and disclosure requirements for
earnings per share for entities with publicly held common stock or potential
common stock.

Net loss per common share - basic and diluted is determined by dividing the net
loss by the weighted average number of shares of common stock outstanding.

NOTE C - DEVELOPMENT STAGE COMPANY

The Company is in the development stage as defined in Financial Accounting
Standards Board Statement No. 7. It has not commenced full scale operations and
has insignificant assets and liabilities. Since inception, the Company did not
have any revenues or earnings. The future success of the Company is dependent on
obtaining a viable business opportunity and /or merger candidate. The Company is
seeking a merger candidate who manufactures and distributes certain generic
over-the-counter drugs. Management is seeking additional investment capital to
support its entrance into a new business opportunity or merger.

NOTE D - RELATED PARTY TRANSACTIONS

1. DUE TO OFFICER/SHAREHOLDER

Since the merger in 1999, Varges George, President and majority shareholder,
loaned the Company $8,068 ($2,800 in 2000 and $6,168 in 2002) for payment of
operating expenses. The Company has paid back $900 ($600 in 2000 and $300 in
2001) leaving a balance of $8,068 at December 31, 2002.

NOTE E - INCOME TAXES

Temporary differences and carryforwards give rise to deferred tax assets and
liabilities. The principal components of the deferred tax assets relate to net
operating loss carryforwards. At December 31, 2002, the Federal net operating
loss carryforwards were approximately $36,000. The net operating loss
carryforwards expire at various dates through 2022, and because of the
uncertainty in the Company's ability to utilize the net operating loss
carryforwards, a full valuation allowance was provided at December 31, 2002,
2001 and 2000. Corporate income tax returns have not been filed since 1999.

F-7

ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND
FINANCIAL DISCLOSURE.

During the acquisition of Omni Assets by the Company, Sobel & Co., LLC
acted as the Omni Asset's certified public accounts. They provided, to the
Company, at that time, audited balance sheets, related statements of operations,
stockholders' deficiency and cash flow statements for the year ended December
31, 1999. Since that time, the Company has had no assets, liabilities, operating
activities, or revenue and has no need to employ the services of an accountant.
Prior reports from the auditors did contain an opinion as it relates to a
"Development Stage" company and its ability to operate being dependent upon
obtaining a viable and successful business opportunity. The disclaimer of the
opinion was not qualified or modified as to uncertainty, audit scope or
accounting principles except for a modification that describes substantial doubt
surrounding the Company's ability to continue as a going concern.

The audited financial statements that accompany this Form 10k, as
amended, were performed by the Company's new auditors, Kahn Boyd Levychin &
Company, after Sobel & Co. resigned in October of 2002, pursuant to Regulation
S-K. A letter that addresses Sobel & Co. resignation is attached hereto.

ITEM 10. DIRECTORS AND EXECUTIVE OFFICERS OF THE REGISTRANT.

IDENTIFICATION OF DIRECTORS.

At present, Inamco has only one director, Mr. Varges George.

IDENTIFICATION OF EXECUTIVE OFFICERS.

At present, Mr. Varges George, age 45, is the sole executive to the
Company. He serves in the capacity of both president and secretary. He has been
the sole executive of the Company since the acquisition of Omni Assets, Inc. by
the Company on October 26, 1999. At present, Mr. George has no arrangements or
understandings between he and any other parties with respect to the Company
except those that are stated herein.

IDENTIFICATION OF CERTAIN SIGNIFICANT EMPLOYEES.

At present, the Company has no employees or understanding with any
persons acting as production managers, sales managers, or research scientists
who are in any way associated with Inamco.

FAMILY RELATIONSHIPS.

There are no relationships between family members of the sole executive and
the Company.

BUSINESS EXPERIENCE.

For the past 10 years, Mr. Varges George has been the president; and sole
shareholder of Inamco Services Corp., a management company that owns and
operates two separate and distinct companies: Medicos Laboratories, Inc. and
Advanced Diagnostics, Inc., descriptions of which are as follows:

MEDICOS LABORATORIES, Inc. operates primarily as a laboratory engaged in
the development and manufacture of non-prescription and prescription generic
drugs. As stated earlier in the Form 10, generic pharmaceuticals, as a whole,
have the same chemical and therapeutic properties as their brand-named
counterparts. Although typically less expensive, they are required to meet the
same governmental standards as the brand-named drug, and most must receive
approval from the appropriate regulatory authority prior to manufacture and
sale. A manufacturer cannot produce or market a generic pharmaceutical until all
relevant patents (and any additional government-mandated market exclusivity
periods) covering the original brand-name product have expired. Medicos, being
an U.S. Food and Drug Administration ("FDA") approved manufacturer, has the
ability to produces both over-the-counter ("OTC") and certain prescription
medications in the forms of tablets and capsules. Medicos, in September of 2002,
received FDA approval to manufacture and sell Phenazopyridine tablets, it's sole
product, and is now researching and developing other niche drug products in
which to produce and distribute. An acquisition has not occurred, for the fact
that Medicos needs to complete certain other business activities, including but
not being limited to, final construction of warehousing areas, and the
completion and consummation of certain other manufacturing and distributing
agreements. The Company anticipates that an acquisition of Medicos could be
consummated by the end of the third quarter of 2003, however there are certain
risks, as explained in other sections of this Form 10, associated to merging the
Company and Medicos, which could curtail and/or suspend any acquisition
contemplated. Readers of this Form 10 report are not to assume that an
acquisition of Medicos is a likely event.

ADVANCED DIAGNOSTICS, INC. is dedicated to the research, development and
manufacturing, and marketing of diagnostic test kits. The company sells its
products through wholesalers, private label distributors, drug chain stores,
health maintenance organizations ("HMO's"), hospital buying groups, and local,
state and federal government agencies. This company produces such products as:
pregnancy tests, allergy indicators, Strep A Testing, ovulation and fertility
testing, tumor markers, drugs of abuse diagnostic kits, and infectious diseases
tests.

Mr. George received the degree of Master of Business Administration from
the Siddharth Institute of Industry and Administration of Bombay, India in 1979.
Mr. George, an accountant by training, has comprehensive knowledge of
import-export markets and of financial operations, which has enabled him to work
in fast-paced, highly diversified environments. While working as the Finance
Manager for Sayco & Al Ordoba in 1981, Mr. George orchestrated international
transactions involving millions of dollars with such multi-national
conglomerates as IBM, Xerox, Amoco Oil and Minnesota Mining and Manufacturing.
Mr. George was Finance and Administration Manager for Al Orooba Technical
Trading Co. of the United Arab Emirates in 1982, Chief Accountant for Step
International Marketing Co. of Bombay, India in 1979, and Accountant for St.
George Automobiles and Thankappan and Madhu, both of Kerala, India in 1977.

DIRECTORSHIPS.

At present, the Company has no directors or understanding with any
persons acting as directors who are in any way associated with Inamco.

ITEM 11. EXECUTIVE COMPENSATION.

Summary of Cash and Certain Other Compensation

The following table sets forth certain information concerning the
compensation paid by the Company for services rendered to the Company in all
capacities for the fiscal years ended December 31, 2002, 2001, 2000 and 1999 by
the Company's Chief Executive Officer:

SUMMARY COMPENSATION TABLE

LONG TERM
COMPENSATION
ANNUAL COMPENSATION AWARDS
------------------------- -------------
CLASS "A"
ALL OTHER COMMON STOCK
ANNUAL RECEIVED BY VALUE OF
NAME AND PRINCIPAL POSITION YEAR SALARY COMPENSATION PRINCIPAL COMPENSATION
- ---------------------------- ------- ---------- -------------- --------------- --------------

Varges George 2002 $ -- $ -- -- . $ 10,000
President and Secretary 2001 -- -- -- 50,000
2000 -- -- -- 1,100,000
1999 -- -- 1,000,000 sh. 2,350,000

In accordance with the rules of the SEC, the compensation described in the above
table, and that was paid to Mr. George, was done so entirely in stock and does
not include any medical payments, group life insurance or any other benefit that
could be received by the sole Executive Officer of the Company. Furthermore,
there has been no compensation awarded to, earned by, or paid to any other
person, acting as an employee, since the Company's acquisition of Omni Assets,
Inc., on October 26, 1999.

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT.

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS.

As of May 9th, 2002, the Company had a total number of shares outstanding
equal to Twenty Seven Million Six Hundred Thousand (27,600,000). The following
table provides information pertaining to owners of more than five percent of any
class of the Company's voting stock.

- -------------------------------------------------------------------------------------------------------------
(1) (2) (3) (4)
Name and Address Amount and Nature Percentage of
Title of Class of Beneficial Owner of Beneficial Owner Ownership
- -------------------------------------------------------------------------------------------------------------

Common A Inamco Services Corp.* 12,947,487 46.91%
801 Montrose Ave.
South Plainfield, NJ 07080

Common A Advanced Diagnostics Inc.* 8,326,403 30.17%
801 Montrose Ave.
South Plainfield, NJ 07080

* It should be noted that Mr. Varges George is the sole shareholder and owner of
Inamco Services Corp., and Advanced Diagnostics Inc., as described above.
Accordingly, Mr. George has direct control and ownership of 21,273,890 shares of
common stock, which represents approximately 77.07% of the Company's outstanding
common shares (this does not take into consideration shares owned personally by
Mr. George, as explained below).

Security ownership of management.

As of May 9th, 2002, the Company had a total number of shares
outstanding equal to Twenty Seven Million Six Hundred Thousand (27,600,000). The
following table provides information pertaining to shares beneficially owned by
all directors and nominees.

- -------------------------------------------------------------------------------------------------------------
(1) (2) (3) (4)
Name and Position Amount and Nature Percentage of
Title of Class of Beneficial Owner of Beneficial Owner Ownership
- -------------------------------------------------------------------------------------------------------------

Common A Varges George* 1,000,000 3.62%
President/Secretary

* Taking into consideration that Mr. Varges George is the sole shareholder of
Inamco Services Corp., and Advanced Diagnostics Inc., it should be noted, that
with the addition of Mr. George's personal shares received as employment
compensation, and described in other sections of this Form 10, he has direct
control of a total of 22,273,890 shares of common stock, which represents
approximately 80.70% of the Company's outstanding common shares.

ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS.

TRANSACTIONS WITH MANAGEMENT AND OTHERS.

The Company has not been involved with or privy to any transactions with
any persons and/or business entities since the Company's acquisition of Omni
Assets, Inc., on October 26, 1999. The acquisition of Omni (Omni being defined
as a "non-operating public shell"), in essence, was by a privately owned
operating company, and for reasons of filing this Form 10, that transaction was
deemed as a capital purchase by a privately-held business. Since that purchase,
Inamco has been dormant with the exception of the limited amount of activity as
described in Item. 1 "BUSINESS" - "General development of business" above.

CERTAIN BUSINESS RELATIONSHIPS.

The Company's sole executive, Mr. Varges George, is currently the president
and sole shareholder of Inamco Services Corp. This management company owns and
operates two separate and distinct companies: Medicos Laboratories, Inc. and
Advanced Diagnostics, Inc., descriptions of both company's stated herein, under
Item 6. "DIRECTORS AND EXECUTIVE OFFICERS" - "Business Experience" of Mr. Varges
George.

Although the Company's sole executive officer and director is also the
owner of record, of Inamco Services Corp., Medicos Laboratories, and Advanced
Diagnostics, neither he nor any other entity has made payment, nor contributed
to the Company's gross revenues or assets in any way whatsoever since the
acquisition of Omni Assets, Inc. on October 26, 1999. As explained in previous
sections of this Form 10 report, net cash provided by loans from Mr. George was
approximately $9,226 during the year ended December 31, 2002, and a total of
$8,068 is owing to Mr. George, from the Company, that is incurring 7% interest
on an annual basis while the debt is outstanding. Net cash proceeds from loans
by Mr. George were $525 during the year ended December 31, 2001.

The Company's sole executive, Mr. George, is not a member of, or of counsel
to, a law firm, nor is he a partner to an investment banking firm, where such a
company would need a retainer in order to perform certain services to Inamco.

INDEBTEDNESS OF MANAGEMENT.

The sole executive of Inamco, Mr. Varges George, has not been indebted to
the Company in any way whatsoever.

TRANSACTIONS WITH PROMOTERS.

The Company has had no need to employ and/or invoke the services of a
promoter.

ITEM 14. EXHIBITS, FINANCIAL STATEMENT SCHEDULES, AND REPORTS ON FORM 8-K.

(a) 1. Financial Statements.

Reference is made to the Index to Financial Statements under Item 8,
hereof.

2. Financial Statement Schedules.

The Financial Statement Schedules have been omitted either because they
are not required or because the information has been included in the notes to
the Financial Statements included in this Report on Form 10k.

3.
EXHIBITS:

EXHIBIT NO. DESCRIPTION
- -------------- -----------
(a) None.

(b) Reports on Form 8-K

None.

See Item 14(a)(3) above.

(d) Financial Statement Schedules

See Item 14(a)(2) above.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized, on April 8, 2003.
Inamco International Corp.
A Delaware Corporation

By: /s/ VARGES GEORGE
--------------------------------
Varges George
Chief Executive Officer

Pursuant to the requirements of the Securities Exchange Act of 1934,
this report has been signed below by the following persons on behalf of the
registrant and in the capacities indicated on April 8, 2003.

SIGNATURES TITLE
- ---------- -----

By: /s/ VARGES GEORGE President, Chief Executive
---------------------------- Officer and Director
Varges George